Efficacy and safety of peginterferon α-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe
2011
Methods: HCV genotype 1 patients previously treated with
conventional interferon with or without ribavirin were assigned
to 48 weeks of treatment with peginterferon alfa-2a (40KD) 180
mcg/week plus ribavirin (recommended dose 1000/1200 mg/day) in
this open-label trial conducted in Central and Eastern Europe.
The primary efficacy endpoint was sustained virological
response (SVR, HCV RNA <50 IU/mL) after 24 weeks of untreated
follow-up. Early virological response (EVR) was defined as
undetectable HCV RNA or minimally 2-log drop at week 12.
Results: 154/203 (76%) treatment-experienced genotype 1
patients completed treatment. Overall, 113 patients (56%)
achieved an EVR, 107 (53%) had an end-of-treatment response and
63 patients (31%) achieved an SVR (including 38% [40/105] of
those with prior breakthrough or relapse and 24% [21/88] of
those with prior non-response). Among patients with an EVR 47%
(53/113) achieved an SVR (positive predictive value = 47%),
compared with 3% (1/34) of patients without EVR.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI